Multiple myeloma is a malignant plasma cell tumor that predominates in men older than 45 years of age. The main symptoms are: bone pain and possible pathological fractures. Anemia, mild anemia in the early stages and severe anemia in the later stages. Hepatosplenomegaly. Renal impairment, with hypercalcemia, hyperphosphatemia, and hyperuricemia. Infection, causing lung and urinary tract infections. Impairment of neurological function, which may cause coma, paralysis and other symptoms. Multiple myeloma drug treatment preferred targeted drugs, currently mainly proteasome inhibitors, preferred bortezomib + dexamethasone, or the addition of lenalidomide.